Skip to content
Review Open access

Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab

Sep 2026 · International journal of urology · Vol 33 · 1 citation · 82 references
Medicine

TL;DR

A deeper understanding of primary resistance will be essential for the development of mechanism‐based therapeutic strategies and for achieving durable clinical benefit in patients with mRCC.

Abstract

Immune checkpoint inhibitors have become a standard treatment for patients with metastatic renal cell carcinoma (mRCC). The combination of nivolumab and ipilimumab has demonstrated durable responses and survival benefits; however, approximately 20%–25% of patients exhibit primary resistance and derive limited clinical benefit. This review provides a comprehensive overview of current evidence regarding the incidence, clinical predictors, and biological mechanisms of primary resistance to nivolumab plus ipilimumab in mRCC. Key contributing factors include an immunosuppressive tumor microenvironment, metabolic reprogramming, interferon signaling abnormalities, and T‐cell exhaustion. Potential strategies to overcome resistance, such as vascular endothelial growth factor receptor–targeted combinations, biomarker‐driven treatment selection, and novel immune checkpoint targets, are also discussed. A deeper understanding of primary resistance will be essential for the development of mechanism‐based therapeutic strategies and for achieving durable clinical benefit in patients with mRCC.

Read PDF

Similar papers

Editorial Open access Sep 2026

Editorial Comment to “Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab”

The treatment landscape for metastatic renal cell carcinoma (mRCC) has changed significantly with the advent of combination therapies based on immune checkpoint inhibitors (ICIs). Currently, nivolumab plus ipilimumab (NIVO+IPI) and ICI plus tyrosine kinase inhibitor (IO–TKI) combination therapies are widely used as fir...

H. Hirata · 0 citations
Review Open access Sep 2026

Overcoming melanoma drug resistance: Mechanisms and clinical progress of oncolytic viruses combined with immune checkpoint inhibitors (Review)

Emerging clinical evidence and mechanistic insights into OV–ICI synergy are synthesized to inform rational trial design, refine combination strategies, and accelerate the development of precision immuno-oncology approaches.

Yuan He, Wen-Xuan Lin, Hao-Fan Chen et al. · 0 citations
Review Open access Oct 2026

Mechanisms of resistance to immune checkpoint inhibitors in renal cell carcinoma and novel treatment strategies

In recent years, immune checkpoint inhibitors (ICIs), such as nivolumab, ipilimumab, pembrolizumab, and atezolizumab have substantially improved the prognosis of patients with advanced renal cell carcinoma. These agents have greatly changed the management of advanced renal cell carcinoma, shifting the treatment paradig...

Li Chen, Jie Cheng, Shi-Long Mao · 0 citations
Review Oct 2026

Immune checkpoint inhibitors in platinum-resistant ovarian cancer: Clinical disappointments, biological lessons, and the reopening of therapeutic opportunities.

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of several malignancies; however, their efficacy in platinum-resistant ovarian cancer (PROC) remains limited. The immunosuppressive tumor microenvironment (TME) in ovarian cancer constitutes a major barrier to effective antitumor immunity, pro...

E. Giudice, A. Spinazzola, C. Floudas et al. · 0 citations
Review Open access Oct 2026

Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Renal cell carcinoma (RCC), particularly its clear-cell subtype (ccRCC), is characterized by metabolic reprogramming and a complex tumor microenvironment that influence responses to immune checkpoint inhibitors (ICIs). Despite clinical advances, therapeutic resistance remains a major hurdle. Here we review the molecula...

M. Milella, Francesco Lasorsa, M. Rutigliano et al. · 0 citations
Open access Sep 2026

Immunotherapy and Targeted Therapy for Metastatic Renal Cell Carcinoma

Lenvatinib plus pembrolizumab provides significant improvements in PFS and objective response compared with sunitinib, while nivolumab plus ipilimumab demonstrates durable long-term survival benefits.

Zhumagazin Zhanabay Derbesinovich · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.